JSE-listed Aspen Pharmacare, whose market value has declined 35% since March 7, said on Monday its shares would start trading on SA’s A2X exchange from April. “We continually strive to identify ways to increase value for our shareholders and the complementary A2X listing offers investors trading benefits while simultaneously providing the prospect of increasing our shareholder base,” said Aspen CEO Stephen Saad. “We will retain our primary listing on the JSE and our issued share capital will be unaffected by the secondary listing,” Saad said. Aspen’s shares, which have been rocked by debt concerns, were 0.1% up at R91.20 on Monday morning. Earlier in March, the global pharmaceutical company’s shares plunged as much as 51% to R68.99 in just two hours after Aspen said in an earnings report that borrowings, net of cash, had increased by R6.7bn to R53.5bn. Prior to releasing its results, Aspen’s shares were at R141.15. Meanwhile, winning over Aspen is another step forward for A2X, which...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now